CLS resolves rights issue for about SEK 39.5 million
The Board decided on a rights issue of units with preferential rights, covered by subscriptions and guarantees.
See the latest news and media coverage for CLS. We track all announcements, press releases, and industry mentions in real time, all in one place.
Developer of laser ablation systems for cancer and neurosurgery
clinicallaser.seLast updated
In short: CLS achieved strong Prism sales growth, secured a 23 MSEK order, and focused its strategy on neurosurgery while resolving a rights issue.
The Board decided on a rights issue of units with preferential rights, covered by subscriptions and guarantees.
The report shows strong growth in Prism sales and a large purchase order of 23 MSEK.
The Annual General Meeting re-elected the board, reduced the share capital by SEK 68.9 million, and granted an authorization to issue shares.
The study found improved survival in recurrent aggressive brain tumor patients treated with LITT and immune checkpoint inhibition.
The medical technology company Clinical Laserthermia Systems has decided on a rights issue that could provide the company with SEK 39.5 million before expenses. Emissionsguiden begins its monitoring. ... The CLS board has...
Lund, Sweden - Clinical Laserthermia Systems AB (publ) ("CLS" or the "Company") today publishes its interim report for January - March 2026. Highlights of First...
Clinical Laserthermia Systems, CLS, has received an order with a total value of approximately 23 million kronor for its neurosurgical Prism business from...
Clinical Laserthermia Systems AB (CLS) today announced it has reached an agreement with its strategic partner on an alignment to accelerate the growth of the...
Track CLS and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to CLS and other trending companies.